329 Financial toxicity and skin cancer care in the US: Population-based survey from 2011-2018

Abstract

The cost of skin cancer treatments in the US exceeded $8 billion annually from 2007-2011 and is expected to rise. Financial toxicity, an emerging concept on the financial burden and distress associated with cancer treatment, is not well understood in the context of skin cancer. This cross-sectional study aimed to examine financial toxicity among people with skin cancer using pooled nationally representative National Health Interview Survey data from adults in 2011-2018. Material, behavioral, and psychological markers of financial toxicity were compared by lifetime skin cancer history (any melanoma, any skin cancer beside melanoma, and no skin cancer) using multivariable logistic regression models, which adjusted for survey year, demographics, insurance status, income, education, medical comorbidities, and lifetime history of non-skin cancer.